Day 2 :
Keynote Forum
Ehab Elhefenwei
Sheikh Khalifa Medical Center, UAE
Keynote: Pharmacology impact on value healthcare provision
Time : 9:00-10:00
Biography:
Ehab Khamis Elhefnawi had completed Physician Executive Master of Business Administration from Haslam College of Business, University of Tennessee, USA in 2015. He has obtained his Maintenance of Certification (MOC), American Board of Anesthesiology in 2014, Diplomat, American Board of Anesthesiology in 2004 and Master of Science in Anesthesiology, Faculty of Medicine, Alexandria University, Egypt in 1995. He has also completed MBChB degree from Faculty of Medicine, Alexandria University, Egypt in 1989. Presently he is working as a Senior Anesthesiologist and Quality Health Manager, Sheikh Khalifa Medical Center (SKMC), Abu Dhabi, UAE. He is a Member of American Society of Healthcare Executive and American Society of Anesthesiologists.
Abstract:
High value healthcare provision is defined by a numerator of high quality and best outcome and cost as a denominator. Both public and private purchasers are in an important position to act as catalysts of change in managing specialty pharmacy and drug administration, “healthcare organizations, payers, and providers need to work together to develop valuebased care delivery models with clear outcome metrics that can be used to develop a value-oriented market place for healthcare services, highlighted the need for new models of healthcare delivery to counter the increasing cumulative costs of healthcare that are threatening affordability without adding value to quality of care. Nobel focused value-based purchasing for specialty pharmacy should be encouraged to create an effectively managed specialty care. Safe, effective, timely efficient, patient centered healthcare provision model that embraces and respects individual patient needs and eliminates unwarranted variation should be emphasized. Integral to this approach is supporting the patient in all areas of public health. Well-integrated population health maintenance programs created by the ACO (accountable healthcare organization), their main focus is to invest in healthy human, maintaining population health and preventing the progression of chronic disease. The American College of Cardiology and the American Heart Association issued a statement in 2014 about including cost-effectiveness, value assessments, and recommendations in practice guidelines and performance measures “to facilitate the achievement of the best possible health within the constraints of available resources.” Its proposed framework follows a textbook definition of cost effectiveness, measuring the cost of therapies relative to the number of quality-adjusted life-years (QALYs) that they provide. The goal of the value framework developed by the Institute for Clinical and Economic is to improve the reliability and transparency of value determinations made by insurers. ICER’s approach does consider cost-effectiveness (cost per QALY) and does not exclude other benefits, disadvantages, and ethical and contextual factors associated with therapies. These include, for example, whether treatment outcomes reduce disparities across patient groups, whether treatments facilitate greater productivity through, for instance, more rapid return to work, improve quality of life, or whether there are any treatment alternatives. Chronic disease management in an ACO & integrated clinical pharmacist: Chronic diseases are the leading cause of death and disability worldwide, and their management accounts for more than twothirds of global healthcare expenditure. As frontline healthcare professionals, community pharmacists are in contact with this patient cohort regularly, are specially trained to reduce disease severity, monitor medication therapy to achieve desired clinical effects, reduce adverse health events, and can make recommendations to patients or prescribers regarding pharmacotherapy where appropriate. Studies have shown that pharmacists in primary care have the skills to manage patients with long-term conditions, and this can result in both clinical and cost benefits for a variety of chronic illnesses, such as cardiovascular disease, chronic obstructive pulmonary disease, and diabetes. Community pharmacists are ideally placed to undertake health screenings for disease prevention and progression, and to aid in the diagnosis of new diseases. Adherence: it could be avoided as Medication nonadherence is an economic burden worldwide, and it is estimated that the annual cost of nonadherence is $100 billion in the US alone
Role of a Hospital pharmacists in value healthcare provision: Hospital pharmacists represent a key component of the multidisciplinary team involved directly in patient-centered care. Reducing LOS is the key to cost savings. Therefore, by preventing ADEs and shortening LOS over a period of time, pharmacists can make substantial cost savings in healthcare budget. Medicines reconciliation and transitions of care: Elderly patients appeared to benefit most from this service. It has been shown that pharmacists’ involvement at admission and discharge has resulted in reduced medication errors and ADEs, as well as a substantial decrease in the rate of all-cause ED visits and hospital readmissions. Pharmacology and personalized or precision medicine: Genomics has helped to initiate the era of precision medicine. Pharmacogenomics is a part of precision medicine. Pharmacogenomics is the study of how genes affect a person’s response to particular drugs. This relatively new field combines pharmacology (the science of drugs) and genomics (the study of genes and their functions) to develop effective, safe medications and doses that are tailored to variations in a person’s genes. Conclusion: Pharmacology science contribute to reductions in costs in a wide variety of healthcare settings, and we should focus on identifying standard practice, essential services and innovative interventions both valuable and effective in the greatest cost savings. With providing the High-quality healthcare that leads to prevent the disease or cure diseases, hence improving population health outcome, we should study socio-economic effect and search which valuable clinical pharmacy services should be implemented.
- Pharmacogenetics and Pharmacogenomics | Pharmaceutical Chemistry, Computer-Aided Drug Design, Medicinal Chemistry| Novel Drug Delivery System (NDDS) | Genetic and Molecular Toxicology |Neuro and Cardiovascular Pharmacology | Pharmacotoxicology |Drug Toxicology and Interaction |Pharmacovigilance & Drug Safety |Recent Advancement in Pharmacology and Toxicology
Location: Conference Hall
Chair
Mohamad Samer Mouksassi
Certara Consulting Services, Canada
Co-Chair
Yogeeswari Perumal
Birla Institute of Technology and Science, India
Session Introduction
Indra Prasad Pandey
Journal of Phyto-chemistry and Ayurvedic Heights, India
Title: Diversity of medicinal plants their scientific uses and conservation in Alaknanda Valley, Uttarakhanda, India
Time : 10:00-10:30
Biography:
Indra Prasad Pandey has Completed PhD in from HNB Garhwal Central University Published 225 papers in national and international Journals. Total no. of Ph.D and D.Sc. conferred are 65 under the guidance. Presently he is the Professor Emeritus, coordinator and Jt. Editor of Universities ‘Journal of Phyto-chemistry and Ayurvedic Heights’.
Abstract:
This study is very important for future generations because the medicinal plants used in various traditional systems for the traditional medicines in the valley of Alaknanda of Uttarkhand Dev Bhumi, India. An ethno-medicinal survey was done in the year 2012-14 in various areas of Alaknanda valley, the information on ethno-medicinal importance of the different plant species were collected through interviews and discussions with the local people living in the Valley. Total 101 plant species are generally used for medicinal purposes were recorded in the survey. In the most of the cases, the underground plants (roots/ rhizomes/tubers) 25% are used for medicinal purposes, 20% leaves, the whole plant 16%, barks 11%, fruits 9%, flowers 7%, stems 5% and seeds 7% of the plants. It is observed that some commercially important medicinal plant species are facing great threat due to habitat degradation, over exploitation and unscientific harvesting in the study areas.
Yogeeswari Perumal
Birla Institute of Technology and Science, India
Title: Multiple crystal structure modeling in structure-based drug discovery: Case studies on successful diverse lead identification
Time : 10:45-11:15
Biography:
Structure-based drug design has played significant role in the design of various drug candidates. The most studied targets include the HIV protease, dihydrofolate reductase, beta secretase etc. for which there are number of crystal structures available in the protein databases (pdb). Our drug discovery research group initiated the strategy of utilizing multiple crystal structures in the design of diverse ligands of human beta secretase and was successful. In continuation to our efforts in this field, we report here the discovery of diverse ligands for various therapeutic classes utilizing structure-based design for those proteins where more than hundred crystal structures were available in the pdb. We rationalized the selection of crystal structures bound with different ligands based on the resolution of the structure, no mutation and only the wild type. About nine to 10 crystal structures were employed in the structure-based drug design to develop energybased pharmacophore (e-pharmacophore) hypothesis based on the ligand interaction with the protein residues. Multiple e-pharmacophores were generated and validated using enrichment factor calculation. The validated pharmacophore hypothesis was utilized for filtering commercial database with pharmacophore fitness above 1.0. A high throughput screening combined with docking, analysis of binding amino acid residues and ADME parameters led to the identification of some potential diverse scaffolds that could be developed as novel inhibitors of HIV protease.
Abstract:
Yogeeswari Perumal is currently working as a Professor and Associate Dean (Sponsored Research and Consultancy Division), Department of Pharmacy, Birla Institute of Technology and Science, Pilani, Hyderabad Campus. She is the Founder of the Yogee’S Bioinnovations Pvt. Ltd, which is a drug discovery unit.
Noon Abubakr Abdelrahman Kamil
Fatima College of Health Sciences, UAE
Title: Development of spectrophotometric methods for the analysis of nicotinamide in bulk and dosage forms
Time : 11:15-11:45
Biography:
This study was aimed to develop simple, sensitive and accurate zero (0D), first (1D) and second (2D) order derivative spectrophotometric methods for the analysis of nicotinamide in bulk and dosage forms. Methods: The zero-order spectrum of nicotinamide aqueous solution was measured at 262 nm against its blank. This spectrum was differentiated instrumentally to generate the first and second derivative spectra which were measured at 272 nm and 278 nm, respectively. The developed methods were validated as per ICH guidelines.The absorbance ratio of nicotinamide absorbance values at 214 nm and 262 nm was also determined. Regression data of the developed methods obeyed Beer’s law over the concentration range 10-50 μg/ml with a good correlation coefficient (not less than 0.998). The developed methods demonstrated good inter-day and intra-day precision at the three modes. The obtained recovery percentage (99.2 ± 2.6%, n=3) reflected freedom from interference by the excipients. The absorbance ratio for nicotinamide at 214 nm and 262 nm was found to be in the range between 2.8- 3.2 which can be used as identification test for Nicotinamide (qualitative analysis). Conclusion: The statistical validation at 95% confidence level proved the sensitivity, accuracy and precision of the developed methods
Abstract:
Noon Abubakr Abdelrahman Kamil has her expertise in pharmaceutical chemistry drug analysis and passion in research and pharmacy education. Her research on drug analysis creates new methods of drug analysis using simple and accurate ways. She has more than ten years of teaching pharmacy students.
Chaitra Harsha
Vipragen Biosciences Pvt ltd, India
Title: Evaluation of ayurvedic formulation against chemical induced chronic pancreatitis in rats
Time : 11:45-12:15
Biography:
Chaitra Harsha is a Medical Doctor with PhD from Indian Institute of Science, India. She has also received Management degree from Indian Institute of Management, Bangalore, India. She is the Managing Director of Vipragen since 2015 and heads a team of 38 highly skilled scientific personnel.
Abstract:
Chronic pancreatitis is characterized by inflammation, fibrosis, and loss of exocrine (acinar cells) and endocrine (islets) tissue. In this study, L-arginine induced chronic pancreatitis model has been developed and the effect of Amar, an ayurvedic formulation on the chronic pancreatitis was studied in male Wistar rats. Animals were treated with vehicle control, Amar (25, 50 and 100 mg/kg/day) and methylprednisolone for a maximum period of 21 days and observed for general clinical parameters, clinical pathology parameters, anti-oxidant levels, inflammatory cytokines and pathological changes. oral (gavage) administration of Amar upto 100 mg/kg/day ameliorated the L-arginine induced changes in Chronic pancreatitis model in male Wistar rats. The treatment of Amar reduced the oxidative stress, the level of inflammatory cytokines levels and structural changes in pancreas. The results showed that antioxidant and anti-inflammatory properties of Amar could be the possible reason for its amelioration effect in L-arginine induced chronic pancreatitis model in male Wistar rats.
Payam Peymani
Shiraz University of Medical Sciences, Iran
Title: Social pharmacy as a social aspect of Pharmco-epidemiology: Now more than ever
Time : 13:15-13:45
Biography:
Payam Peymani is currently an Assistant Professor and Director of Pharmacoepidemiology and Pharmacoeconomics Group, Health Policy Research Center of Shiraz University of Medical Sciences. Also, He is a Director of Accreditation and Ranking Directorate, Vice Chancellery for Global Strategies and International Affairs, Shiraz University of Medical Sciences Shiraz, Iran. He is the author of more than 40 peer review papers, and participated and gave presentation in more than 34 international Congress and symposia and has been a reviewers of various international scientific journals. He is a Member of Pharmacoepidemiology Committee of Shiraz University of sciences. He is an Editorial Manager and Associated Editor of the Social Pharmacy Journal. Dr. Peymani has a more than 6 years' experience of designing and conducting clinical trials, Pharmacoepidemiology , population Based and social pharmacy Study. Dr Peymani obtained his MPhil of Health Policy and PhD of Clinical Pharmacology (Pharmacoepidemiology) from Health Policy Research Center, Shiraz University of Medical Sciences in 2013 and 2016 respectively. He received his Pharmacy Doctorate (Pharm.D) degree in Pharmaceutical Sciences from Faculty of Pharmacy, Shiraz University of Medical Sciences in 2010.Currently, His is involved in Pharmacoepidemiology, Pharmacovigilance and population Based study and his main research interest is in the design and conduct Clinical Trial and Pharmacoepidemiology / drug safety evaluation.
Abstract:
Since pharmacy is increasingly assuming the role of ‘primary and secondary health care professionals’, rather than being solely dispensers of medicines and suppliers of medical appliances, pharmacy students and researchers require new proficiencies as communicators, problem-solvers and advisers. ‘Social, behavioral and cognitive science’ has been identified as having a significant contribution to make in the educational training of pharmacists. In this lecture we are concerned specifically with the application of sociology to the practice of pharmacy. Social pharmacy is a file riven by social demands. By studying the relationship between pharmaceutical sciences, society and humanistic perspectives, particularly through case studies, the impact of medication and changes in societal expectation of them, as well as through historical background studies and surveys of current movement, this field acts to determine the roles of pharmacists and pharmacies expected by society. Social pharmacy requires a basic knowledge of pharmaceutical science, but an understanding from socio-economic viewpoints of the current status and structures in which healthcare functions is important as well. So far, social pharmacy has played a vital and necessary role in training curriculum for community-based pharmacists. Social pharmacy may be seen as including of all social indicators influencing the use of a particular drug, like drug-related beliefs, regulations, policy, knowledge, attitudes, practice, medicine information, ethics and behavior. Social pharmacy programs in pharmacy curricula are becoming more crucial and essential because of the various factors that can affect the health of a society. Social pharmacy deals with the study of community and human act and as a behavioral science is often related with disciplines that deal with individuals as well as large and small groups, including psychology, sociology and anthropology. So it can be discussed that social pharmacy begins with a rationale of social, cognitive and behavioral sciences to educational course for pharmacists and its inclusion in the curriculum and also establish of departments, centers and journals of social pharmacy, which is a prerequisite for the development of the concept of social pharmacy and its further implementation in real world evidence and practice.
Biography:
Abstract:
Veronika furlan
University of Maribor, Slovenia
Title: [6]-Gingerol as a natural scavenger of chemical carcinogens - A computational approach
Time : 14:15-14:35
Biography:
Abstract:
Saliha Aysenur CAM
Beyazit University, Turkey
Title: Nigella sativa and thymoquinone ameliorate memory impairment and neuroinflammation in Aβ-induced rat model of Alzheimer's Disease
Biography:
Abstract:
Heba Moustafa Mohamed
Cairo University, Egypt
Title: Towards disposable sensors, recent developments and pharmaceutical applications of screen printed electrodes
Biography:
Heba Moustafa has her demonstrated research expertise in pharmaceutical analysis, passionate to work at the interface of chemistry and biology towards better patients’ health and safety. Strong technical skills in analytical techniques; spectroscopy (Mass spectroscopy, NMR, spectrophotometry), chromatography (LC/MS/MS, UPLC-MS/MS, HPTLC, HPLC) and electrochemical methods, in addition to educational research. She completed her MSc and PhD degrees in pharmaceutical analysis from faculty of Pharmacy, Cairo University-Egypt. She has published more than 25 papers in highly reputed international journals and has been serving as reviewer for many highly esteemed journals and participated in different international conferences.
Abstract:
The combination of modern electrochemical systems along with screen printing technology give an amazing chance for the introduction of potential and powerful analytical tools for efficient monitoring and analysis of pharmaceuticals, biomarkers and metabolites, environmental and food pollutants. Screen-printed electrodes (SPEs) can successfully address the time constraints associated with the conventional laboratory analysis. The adaptability and low-cost of this technology is accountable for its nonstop expansion and the continuous grow within the SPEs field to discover new areas of applications. Their improvements mainly will depend on incorporating new printed materials, new ligands, new polymers, further nanostructure materials and new supports. Recently, SPEs are coupled to biomolecules with the assistance of modern electroanalytical techniques and offers an excellent chance for therapeutic drug monitoring. In this work, detailed description of the elementary fabrication principles, the different designs of SPEs and the different analytical methods that are based on SPEs will be presented. Special emphasis is given on the electrochemical application of SPEs in pharmaceuticals analysis, their recent designs and the future perceptions.